Unilever Raises Growth Target to 4-6% After Foods Separation, But Valuation Still Stretched

What happened

Unilever announced a revised growth framework targeting 4-6% annual underlying sales growth, with volume growth of at least 2%, as it prepares to become a more focused beauty, personal care, and home care company following the planned separation of its Foods business. This new target is an uplift from the prior 3-5% multi-year range outlined in the last annual report, and comes on top of the earlier decision to demerge its Ice Cream unit, leaving two major portfolio restructurings underway. Management's plan implies a step-up in organic growth from the 4.2% underlying sales growth achieved in 2024 and the 3% reported in Q1 2025, even as competitive and cost pressures persist. The market has responded modestly, with the ADR trading around $61 in early November 2026, but according to a DCF analysis from December 2025, the stock is still about 39% above estimated intrinsic value of roughly $43 per share. While the sharper focus on higher-growth categories could support a premium multiple over time, the company must first execute the Foods separation without value leakage and demonstrate that the higher growth target is achievable, not just aspirational.

Implication

The raised guidance to 4-6% underlying sales growth is a positive signal that management expects the post-Foods portfolio to be structurally faster-growing, but investors should scrutinize whether this is backed by concrete category momentum or merely a rebasing exercise. Separation of Foods will reduce diversification and expose the company more to competitive beauty and personal care markets, where Unilever has shown strength but also faces intense competition from premium and indie brands. Execution risk is material: the Foods separation comes on top of the Ice Cream demerger and the €800 million productivity programme, and dis-synergies or distraction could offset the benefits of a narrower business. From a valuation perspective, the stock still trades at a high ~32x trailing P/E and roughly 39% above our DCF estimate, leaving little margin of safety for any disappointment in hitting the new targets. We would need to see sustained volume growth above 2% and margin expansion before upgrading from a potential sell stance; a pullback toward the high-$40s to low-$50s range would offer a more attractive risk-reward.

Thesis delta

Management's announcement of a 4-6% growth target after Foods separation represents a modest positive shift in strategy, suggesting a leaner, higher-growth portfolio, but it does not resolve the key overvaluation issue. The additional separation adds execution risk to an already complex transformation, and we maintain a cautious potential sell stance until the company can demonstrate that the higher growth is achievable without margin sacrifice. The fundamental gap between market price and intrinsic value remains wide, so no change to our valuation-based negative bias.